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Menopause is defined as the permanent cessation of menses. Cardiovascular disease is the leading cause of death among
postmenopausal women in developed countries. The disparity between the incidence of cardiovascular disease among women in
pre- and postmenopause has been ascribed to the actions of endogenous estrogen on the cardiovascular system and, particularly,
on the vascular endothelium. The endothelium plays an important role in cardiovascular homeostasis, either through the vascular
tonus and its regulation, or through coagulation and the inflammatory response. Endothelial dysfunction is implicated in the
genesis of atherosclerosis and other chronic disorders, such as diabetes mellitus and hypertension. The pharmacological use of
estrogen exerts influence on the circulating levels of markers of vascular tonus, and inflammation, as well as prothrombotic, and
fibrinolytic markers, but the impact of these changes on the atherosclerotic disease is still uncertain.
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Menopause is defined by the World Health Organiza-
tion as the permanent cessation of menses as a result of
the loss of ovarian follicular function or of surgical removal
of ovaries.1 The mean age for occurrence of natural meno-
pause is around 50 years.1,2
The management of the menopausal patient has been
a matter of great concern in the last decades, both in terms
of epidemiology and public health and in terms of medi-
cal scientific research. This is largely due to improved life
expectancy, which allows the prediction that women may
live a third of their lifetimes after menopause. Demo-
graphic studies indicate that worldwide in 1990, about 467
million women were at age 50 or over. For the year 2030,
the estimate is that this group will exceed 1200 million
women.3
The hormonal changes that accompany menopause, par-
ticularly the decreased levels of estrogen hormones, have
a great physiological impact. Estrogen deficiency has been
associated with vasomotor symptoms, urogenital atrophy,
and cognitive impairment, as well as increased risk of
chronic degenerative diseases such as osteoporosis and
Alzheimer’s disease.
MENOPAUSE AND CARDIOVASCULAR DISEASE
Cardiovascular disease remains the leading cause of
death in the 21st century.4 Despite the advances in this
area, it is still the main cause of death among women
in developed countries. In the United States, over half a
million women die of cardiovascular disease every year,
exceeding the number of deaths among men and the to-
tal of the subsequent leading causes of death among
women. Coronary arterial disease is responsible for most
of the deaths by cardiovascular disease among women.5
Moreover, women have a less favorable prognosis than
men with respect to a coronary event: 40% of the total
coronary events in women are deadly, and 67% of sud-
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den deaths occur in women without a history of coro-
nary disease.5
The prevalence of cardiovascular disease in premeno-
pausal women is smaller than in postmenopausal women,
when there is an exponential increase, causing the risk for
women to equal that for men by the age of 70 years. This
lag concerning the age period at which the frequency of
cardiovascular events increases among women as compared
to men has been ascribed to the actions of endogenous
estrogen on the cardiovascular system, through mechanisms
as yet not completely clarified.
The beneficial influence of hormone therapy (HT) dur-
ing menopause on the cardiovascular comorbidities is not
well-established. Observational studies have found a re-
duction of up to 50% in the risk of cardiovascular dis-
ease in postmenopausal women using HT.7–9 However, the
results of 2 large randomized prospective studies refute
the claims of cardioprotective effects of hormone therapy
based on observational studies. The Heart and Estrogen/
Progestin Replacement Study (HERS) was a randomized
clinical trial designed to test the effectiveness of HT in
the secondary prevention of coronary heart disease. The
results indicate an increase in the coronary events within
the first year of follow-up after acute myocardial infarc-
tion among patients treated with a combination of conju-
gated estrogens/medroxy progesterone acetate at fixed
doses and mean age of 66.7 years.10 Recently, the Wom-
en’s Health Initiative (WHI), a prospective study of pri-
mary prevention of cardiovascular disease, was interrupted
early because a higher incidence of cardiovascular events
was demonstrated among the women randomized for use
of HT than in the group receiving placebo. In this study,
although HT was associated with reduced risk of
colorectal cancer and bone fracture, it was also associ-
ated with increased risk of breast cancer.11 Finally, in 2004
the results of the therapeutic arm of the WHI evaluating
the isolated use of conjugated estrogens versus placebo
among 10 739 hysterectomized postmenopausal women
were published. There was an increased risk of cerebral
vascular accident (rr = 1.39 CI: 110-177), but a decreased
risk of hip fracture and null effect on the incidence of car-
diovascular disease, as well as potential reduction in the
incidence of breast cancer. Overall, the risk-benefit index
was neutral.12
The well-known risks for cardiovascular disease, such
as systemic hypertension, smoking, obesity, sedentary life
style, dyslipedemia, stress, family history of cardiovascu-
lar disease, diabetes mellitus, and insulin resistance, are
numerous.6 More recently, endothelial vascular dysfunction
has become suspected as being associated with cardiovas-
cular disease, as detailed below.
THE ENDOTHELIUM
The endothelium is a layer of cells lining all the vessels
of the organism and placing itself between the blood and the
vascular smooth muscle layer. The endothelial cells form the
more exposed surface of the inner vascular layer, presenting
selective permeability, having a nonthrombogenic character,
exhibiting exuberant metabolic activity, and having the abil-
ity to produce several vasoactive substances.13
The main actions exerted by the endothelium can be
described as the following:
• Selective permeability: The endothelium forms a highly
selectively permeable barrier, regulating the flow of
nutrient substances, many biologically active molecules,
and blood cells.14
• Maintenance of a balance between thrombosis and fi-
brinolysis: The endothelium normally provides a
nonthrombogenic surface due to its ability to form pros-
taglandin derivatives, especially prostacyclin, which is
a potent vasodilator and an effective inhibitor of plate-
let aggregation.15 The endothelial cells also secrete
agents (including plasminogens) that are effective in the
lysis of coagula, but they also synthesize procoagulant
agents such as Von Willebrand factor (vWF). Addition-
ally, they produce thrombogenic substances such as co-
agulation factors, adhesion molecules, plasminogen ac-
tivator inhibitor-1 (PAI-1), and tromboxan A2.16
• Inhibition of cell proliferation of vascular smooth mus-
cles, preventing the migration of smooth muscle cells
through direct mechanisms, such as synthesis of nitric
oxide, which inhibits cell proliferation, and/or indirect
ones (platelet action).17,18
• Active participation in immune response through the re-
lease of factors leading to active contraction, control of
plasma extravasation, as well as increase in the expres-
sion of integrins, molecules of adhesion and secretion
of cytokines, allowing the migration of monocytes,
lymphocytes, and neutrophils and greater local phago-
cytic activity.
• Modulation of vascular tonus through the production of
numerous vasoactive substances (Table 1). The regula-
tion of the vasomotor tonus is determined by a balance
Table 1 - Endothelial-derived vasoactive factors21
Vasodilator Factors Vasoconstrictor Factors
• Nitric oxide (NO) • Endothelin (ET)
• Endothelium-derived • Prostanoids (PGH2, TXA2, O2)
• hyperpolarizing factor (EDHF)
• Prostacyclin (PGI2) • Angiotensin (AII)
• Acetylcholine
• Bradykinin
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of dilation and constriction. Nitric oxide (NO) is the
main mediator of vasomotor tonus in physiological situ-
ations. Some stimuli, such as the dragging force pro-
duced by the pulsatile blood flow, the pressure of blood
against the vascular wall, and the shear stress, contrib-
ute to the basal generation of NO.19–21
ENDOTHELIAL DYSFUNCTION
The term endothelial dysfunction is more frequently
used to mean reduction in endothelium-dependent vasodila-
tation, associated with diminished bioactivity of local
vasodilating factors, especially nitric oxide, but it probably
includes other normal functions of the endothelium such
as interaction with leukocytes, platelets, and regulatory sub-
stances. Currently, it is a consensus that endothelial dys-
function is the initial event in development of atheroscle-
rosis.22 Several conditions such as aging, menopause,
dyslipedemia, high blood pressure, and diabetes mellitus
are associated with endothelial dysfunction.23–27
TECHNIQUES FOR EVALUATION OF
ENDOTHELIAL FUNCTION
There are many techniques for investigating the en-
dothelium, from those that focus on cellular and molecu-
lar aspects, through methods involving tissue culture and
molecular biology tools, to clinical trials applied to human
beings, using invasive and noninvasive procedures to evalu-
ate endothelium-dependent vasodilatation, or the determi-
nation of plasmatic substances that indicate endothelial ac-
tivation and damage (Tables 2 and 3).
Intracoronary studies evaluating endothelium-depend-
ent vasodilatation after infusion of acetylcholine are con-
sidered gold standard techniques in assessing endothelial
function, but their invasive character precludes their large-
scale use.22 Thus, taking into account that endothelial dys-
function is present at early stages of atherosclerosis and that
it involves several arteries, noninvasive tests in the periph-
eral circulation have been increasingly used. 25 Three tech-
niques are particularly useful for estimating the endothe-
lial dysfunction in peripheral circulation: ultrasonography
of brachial artery, impedance pletismography, and dorsal
hand vein compliance. Each of these techniques evaluates
the endothelial function indirectly by measuring changes
to the size of brachial artery, forearm veins, and back of
the hand, respectively, after physical (active hyperemia) or
pharmacological stimulation (bradykinin or acetylcholine).
ULTRASONOGRAPHY OF BRACHIAL ARTERY
Flow-mediated dilatation (FMD) can be measured
through high resolution ultrasonography. This technique
contrasts the changes in the diameter of the brachial ar-
tery in response to the increased flow induced by reactive
hyperemia and sublingual nitrate. Vasodilating responses
are expressed as a percentage of change to the size of the
vessel (basal and following stimulation). In 1994
Celermajer et al28 studied more than 500 healthy individu-
als using FMD and demonstrated negative association be-
tween FMD and a variety of cardiovascular risk factors,
such as smoking, hypertension, age, and hypercholes-
terolemia. Other studies have demonstrated a positive cor-
relation between FMD and central hemodynamic param-
eters as well as the extent and prognosis of the coronary
disease.29,30
Although FMD has been used in several studies, it has
limitations related to environmental and individual factors,
such as prandial state and arterial size.31 Also, problems re-
lated to reproducibility and intraobserver variation are mat-
Table 2 - Markers of endothelial function24,91
Endothelial Function Marker
Coagulation • Fibrinogen
• vWF
• TXA2
Fibrinolysis • t-PA
• PAI-1
Inflammation • CRP
• E-selectin
• fibrinogen
• ICAMs and VICAMs
• IL-6
Vascular Tonus • Plasma Markers
- ET-1
- NO
vWF: von Willebrand factor; TXA2,: tromboxan; A2; tPA: tissue plasminogen
activator; PAI-1: plasminogen activation inhibitor-1; CRP: C-reactive protein;
ICAMs: intercellular adhesion molecules; VICAMs: vascular cell adhesion
molecules; IL-6: interleukin 6; ET-1: endothelin-1; NO: nitric oxide
Table 3 - Functional tests for endothelial-dependent
vasodilation evaluation24,90
Functional Tests
§ Invasive Coronary angiography
Pletismography
§ Noninvasive Positron emission tomography
FMD
Brachial artery ultra-son
Pletismography and dorsal hand vein
compliance method
FMD: flow-mediated vasodilation
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ters of debate in the literature. Rossi et al,32 demonstrated
variation coefficients of 3.3% and 12.4%, respectively, for
basal size and after stimulation of the brachial artery.
There is as yet no consensus in literature about the pa-
rameters of normality for FMD. Ryliskyte et al33 analyzed
115 individuals with low cardiovascular risk and found that
the only independent predictors of FMD were age and ves-
sel size. Therefore, these authors suggest that in analyzing
results, normal ranges according to age and the caliber of
the tested vessel must be taken into account.
IMPEDANCE PLETHYSMOGRAPHY AND
DORSAL HAND VEIN COMPLIANCE
Compliance and vein occlusion pletismography uses a
sensor of stretching to quantify variations in volume in the
forearm or lower limb, taking into account the fact that
variations in volume in these parts are dependent on the
local blood flow variation. Forearm blood flow (FBF) meas-
urements can be done following ischemic (reactive
hyperemia) or pharmacological stimulation, the latter re-
quiring catheterization and drug infusion into brachial ar-
tery, which is an invasive procedure. Flow values can be
calculated by manual or semi-manual analysis using spe-
cific software.
Forearm blood flow has been validated in several stu-
dies as a tool for evaluating the endothelial function. Di-
minished FBF is associated with increased thickness of
the tunica media of the artery as well as presence of CAD
and the risk factors associated with it.16,34,35 Forearm blood
flow can also be used to monitor the changes to the en-
dothelial function after interventions for cardiovascular
risk factors.36
Environmental and physiological variables, such as
room temperature, age, race, hormonal state, phase of men-
strual cycle, anxiety, and prandial state, can influence the
magnitude of FBF responses. Variation in FBF values in a
single individual can be about 12.9%, reflecting the influ-
ence of these variables.37,38 To minimize variability, the tests
must be done in a silent room at a stable temperature, and
the patient must be fasting.
The dorsal hand vein compliance technique uses meas-
urements of venous diameter variations obtained through
a linear transducer. Venodilatation curves are obtained af-
ter infusion of acetylcholine or bradykinin (endothelium-
dependent vasodilatation) and nitrate (endothelium-inde-
pendent vasodilatation) as compared to basal curves.39 Re-
garding safety, risks, and accuracy, the dorsal hand vein
compliance technique is comparable to impedance plethys-
mography, although it has the advantage of using vasoac-
tive substances at lower doses, thus avoiding potential sys-
temic confounders.22 Again, the results are influenced by
environmental and physiological factors. Greater reproduc-
ibility and smaller intrapatient variability of the test are re-
lated to preconstriction of the tested vessel, ideally about
80% of the vein constriction in the basal state (ED80).39
ESTROGEN, MENOPAUSE, AND ENDOTHELIAL
FUNCTION
There is evidence of an association between endothe-
lial dysfunction and reduced endogenous production of
estrogens after natural or surgical menopause or premature
ovarian failure (POF) in women with or without coronary
arterial disease.27,40–42
The actions of endogenous estrogens on the cardiovas-
cular system can be mediated directly on the vessels or in-
directly through the modulation of cardiovascular risk fac-
tors, as well as on the lipid profile (reduction of total cho-
lesterol and LDL, increase in HDL), as already described
more than 20 years ago.7 More recently, studies have also
demonstrated an antioxidant effect by estrogen, reducing
LDL oxidation in vivo and in vitro.43
The direct effects of estrogen on the vascular system
and which modulate the vascular tonus comprise 1) acute
vasodilatation, increasing the synthesis and bioactivity of
nitric oxide;44,45 2) long-term modulation of vascular tonus,
regulating the production of prostaglandins and expression
of eNOS and the endothelin gene46; 3) inhibition of
endothelin-induced vasoconstriction47; and 4) inhibition of
sympathetic activity.27
In addition to these actions on the vascular tonus,
estrogen exerts an antiproliferative action on the vascular
smooth layer.48 Also, it appears to have a major role in vas-
cular remodeling, inhibiting the proliferation of the inner
layer after injury 49 and increasing the expression of con-
tractile proteins in the myocardium.50
In other tissues, such as the liver, estrogen can mediate
both beneficial (expression of genes of apoproteins that
improve the lipid profile) and adverse effects (increase in
the expression of procoagulant factors and decrease of fi-
brinolytic factors).51
From the clinical point of view, our group has recently
reported, in postmenopausal women who were not on hor-
mone therapy, a positive association between nitric oxide
and the free estradiol level, confirming the influence of this
steroid on the endothelial function.52
On the other hand, androgen and sex hormone-binding
globulin (SHBG) levels have been associated with risk of
cardiovascular disease in pre- and postmenopausal
women.53,54 An increase in circulating androgens appears
to be associated with insulin resistance and a predictor of
81
CLINICS 2007;62(1):77-86 Menopause, estrogens, and endothelial dysfunction
Maturana MA et al.
diabetes mellitus.55–57 In a previous study, we demonstrated
a positive association, independent of obesity, between tes-
tosterone levels and hyperinsulinemia in postmenopausal
women with no clinical evidence of cardiovascular dis-
ease.58
HORMONE THERAPY AND ENDOTHELIAL
FUNCTION
Disturbances in endothelial function have an important
role in the physiopathology of atherosclerosis, and several
lines of evidence suggest that interventions in endothelial
function could modify the progress rates of atherosclerotic
disease and the risk of cardiovascular events. A number of
studies have tested the impact of the use of HT on endothe-
lial function using inflammatory and fibrinolytic/thrombo-
genic markers as well as functional methods.40,41,59,60,61
Results from the main randomized studies, HERS 2
and WHI, indicate increased risk of venous thromboem-
bolism with the use of HT.8,62 It is important to note that
these studies have been criticized in at least 2 respects:
patient selection, which included women who were on
average 10 years older than the age at which HT is usu-
ally recommended (WHI), and the use in both studies of
a regimen of HT with fixed drugs, oral administration
route and doses.
The administration route of HT appears to affect the fi-
brinolytic activity and the coagulation markers. The oral
route for estrogen therapy is associated with changes in the
levels of coagulation and fibrinolysis markers, especially
at the early period of use.63–65 Studies using estrogen therapy
by transdermal route, however, did not confirm these find-
ings.66,67 Moreover, in a multicenter case-control study,
Scarabin et al68 evaluated 155 postmenopausal women hos-
pitalized because of venous thromboembolism (VTE) and
demonstrated an increased risk for VTE with oral, but not
with transdermal, therapy. Our group showed in postmeno-
pausal patients that reduction of antithrombin III, usually
seen with oral estrogen therapy, did not occur with the use
of estradiol-17β in the form of percutaneous gel either
alone69 or in association with micronized progesterone71
(Figure 1). Plasma rennin activity was also similar before
and during this non-oral hormone therapy (Figure 1). These
findings have also shown that progesterone does not ap-
preciably attenuate estradiol-induced beneficial effects.
In addition, we have recently shown that, in a sample
of hypertensive postmenopausal women, the association of
non-oral estradiol-17β and low doses of vaginal micronized
progesterone for 1 year were effective on climacteric symp-
toms and safe regarding maintenance of blood pressure con-
trol and preventing endometrial hyperplasia.70,71 Moreover,
in those patients, serial echocardiograph scans showed no
Table 4 - Echocardiographic variables in 20 hypertensive postmenopausal women71
Before HT 6-month 12-month P
Left ventricle posterior wall (mm) 9.1 ±0.4 8.3 ± 0.3 8.0 ± 0.2 0.042
Ejection fraction (%) 71.3 ± 1.3 67.9 ± 1.2 69.4 ± 1.5 NS
Interventricular septum (mm) 9.2 ± 0.4 8.9 ± 0.4 8.2 ±0.2 NS
Blood pressure control was achieved by administration of amlodipine at individually adjusted doses. Hormone therapy was introduced in a cyclic
regimen (21 of 28 days) with percutaneous estradiol (1.5 mg/day) and vaginal micronized progesterone (100 mg/day).
Figure 1 - Renin activity and antithrombin III in 20 postmenopausal women with mild to moderate hypertension, before and during 1 year of non-oral
natural estradiol and low dose of micronized progesterone71
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change in left ventricle mass, but a significant reduction
in the thickness of the posterior wall of the left ventricle
was observed71 (Table 4).
A number of studies have highlighted the effect of HT
on endothelial inflammatory markers, such as decreased
expression of adhesion molecules like ICAM-1, VICAM-
1, and E-selectin.72–74
Studies using the oral route have shown an increase in
the circulating levels of C-reactive protein (CRP), a well-
known inflammatory marker.73–75 However, the clinical sig-
nificance of these results has not been totally clarified.
Other trials with non-oral routes reported, on the contrary,
stability in CRP levels during HT.73,76
Acute non-oral use of estradiol may increase endothe-
lium-dependent vasodilatation.77,78 Saitta et al79 compared
the effects of using 17-β estradiol plus norethisterone,
raloxifene, or placebo for 6 months in postmenopausal pa-
tients. Treated women in both groups showed a significant
increase in endothelium-dependent vasodilation measured
by ultrasonography of brachial artery and in the plasmatic
nitrite/nitrate levels, which was not observed in placebo
users. A significant increase in the NO metabolites levels
has also been shown by Balci et al80 with the use of
transdermal 17β estradiol, 100 mg/week for 3 months.
Although there is some evidence suggesting a favorable
action of HT on vasomotor endothelial function, the long-
term benefits on the natural history of atherosclerotic dis-
ease are as yet unknown. Ceballos et al81 showed a signifi-
cant increase in endothelium-dependent vasodilation in
menopausal patients treated with a combination of
transdermal 17β estradiol and micronized progesterone, but
this benefit was lost after 6 months of drug discontinuation.
Few studies in the literature have addressed the ques-
tion of the effect of progestogens on cardiovascular risk,
and despite the well-recognized benefits of estrogens, con-
troversy surrounds the risks and negative aspects of com-
bined estrogen and progestogen use in HT.
The vascular actions of progestins and progesterone are
mediated by progesterone receptors, expressed in endothelial
cells and the vascular smooth muscle as well as through down-
regulation of the estradiol receptor.45 Concerning progester-
one, evidence suggests that the natural molecule facilitates the
inhibitory effects of estrogen on vascular smooth muscle pro-
liferation82 and may induce endothelium-dependent vascular
relaxation.45,77 In addition, natural progesterone used in HT
appears to preserve the beneficial actions of estrogen.8,70,71
Progestins present different pharmacological profiles
according to their molecular structure, dosage, and to the
presence of comorbidities. As with estrogens, the various
progestins used in HT may differ significantly as to how
closely they mimic their natural counterparts. For instance,
progestin molecules with androgenic properties may an-
tagonize estrogen-dependent beneficial effects on lipids,83
and a new molecule with antimineralocorticoid activity
may reduce blood pressure in postmenopausal women with
hypertension.84
Progestins added to estrogen therapy seem to increase in-
flammatory markers.72 In addition, medroxyprogesterone ac-
etate associated with conjugated equine estrogens produces
no effects85 or inhibits endothelium-dependent vasodilatation
stimulated by estrogens.86 These observations have been taken
to explain, at least in part, the adverse results observed in the
large prospective, randomized, placebo-controlled trials of
combined HT—the WHI and HERS studies. However, the
extent to which findings of these studies of
medroxyprogesterone acetate and conjugated equine estrogens
apply to other HT formulations is unclear at present.
ENDOTHELIAL DYSFUNCTION AND
CARDIOVASCULAR DISEASE PREDICTORS IN
MENOPAUSE
Data from prospective trials have been confirming the
hypothesis that endothelial dysfunction precedes the emer-
gence of chronic disorders. The MONICA/KORA study
(Monitoring of Trends and Determinants in Cardiovascu-
lar Disease/Cooperative Research in the Region of
Augsburg), which involved more than 2000 patients, found
an association between increased levels of E-selectin and
I-CAM and increased risk of diabetes mellitus type 2 (DM-
2).87 In a follow-up study of 840 postmenopausal women,
Rossi et al32 showed an adjusted relative risk for DM-2 of
5.87 (95% confidence interval, 4.34-8.10) in patients in the
lowest tertile of FMD (≤ 4.3).
In addition to effects on endothelial markers, changes
in other factors of cardiovascular risk have been associated
with the menopausal transition, such as the lipid profile,88
weight, and body fat distribution.89,90 The association be-
tween prevalence of cardiovascular risk during
perimenopause and postmenopause and tunica media thick-
ness (TMT) of the carotid was monitored in 314 women
by Matthews et al.88 In premenopausal patients, arterial and
pulse pressure, LDL, HDL, triglycerides, and BMI values
were predictors of TMT and the presence of atherosclerotic
plaque after 5 years of menses cessation. In postmenopau-
sal patients, only the increase in pulse pressure was a pre-
dictor of carotid intimal-medial thickness.91 These findings
support the notion that women at higher risk of cardiovas-
cular disease can be identified during premenopause, and
it is in this period that strategies must be implemented to
prevent the development of atherosclerosis in the postmeno-
pausal years.
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Endothelial dysfunction can be curtailed by nonphar-
macological measures, such as physical activity92 and weight
loss,93 or pharmacological ones, such as statins and angiotensin
converting enzyme (ACE) inhibitor.94.95 The indication for HT
use must be individualized, taking into account the presence
of climacteric symptoms and their impact on inflammatory and
coagulation markers, since long-term benefits regarding athero-
sclerotic vascular disease have not yet been determined.
RESUMO
Maturana MA, Irigoyen MC, Sprtizer PM. Menopausa,
estrogênios e disfunção endotelial: aspectos atuais. Clin-
ics. 2007;62(1):77-86.
A menopausa é definida como a cessação permanente das
menstruações. A doença cardiovascular é a principal causa
de mortalidade em mulheres na pós- menopausa, em países
desenvolvidos. A disparidade entre a incidência de doença
cardiovascular entre mulheres na pré e pós menopausa tem
sido atribuída a ações do estrogênio endógeno sobre o
sistema cardiovascular e, em especial, sobre a função do
endotélio vascular. O endotélio tem importante papel na
homestase cardiovascular, seja no controle do tônus e
permeabilidade vascular, ou da coagulação e resposta
inflamatória. A disfunção endotelial está implicada na
gênese da aterosclerose e de outras doenças crônicas, como
diabete melito e hipertensão arterial. O uso farmacológico
de estrogênio exerce influência sobre concentrações
circulantes de marcadores do tônus vascular, inflamatórios,
pró-trombóticos e fibrinolíticos, porém o impacto destas
alterações sobre a doença aterosclerótica ainda não está
determinado.
UNITERMOS: Menopausa. Função endotelial. Doença
cardiovascular. Estrogênio. Terapia hormonal.
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